Prognostic impact of number of examined lymph nodes on survival of patients with appendiceal neuroendocrine tumors

Table 1 Demographics and clinicopathologic characteristics

Factor	Category	mean ± SD/n (%)
Age	mean ± SD, yr	44.59 ± 18.15
Year	1975-1980	141 (3.08)
	1981-1990	128 (2.79)
	1991-2000	274 (5.98)
	2001-2010	1163 (25.38)
	2011-2016	2877 (62.77)
Race	White	3932 (87.34)
	Black	375 (8.33)
	Other	195 (4.33)
Sex	Male	1972 (43)
	Female	2611 (57)
Grade	Grade 1	1857 (72.59)
	Grade 2	408 (15.96)
	Grade 3	248 (9.69)
	Grade 4	45 (1.76)
Histological type	Large cell neuroendocrine carcinoma	6 (0.13)
	Small cell carcinoma	1 (0.02)
	Carcinoid tumor	2266 (49.44)
	Enterochromaffin cell carcinoid	25 (0.55)
	Goblet cell carcinoid	1033 (22.54)
	Mixed adenoneuroendocrine carcinoma	366 (7.99)
	Adenocarcinoid tumor	417 (9.10)
	Neuroendocrine carcinoma	419 (9.14)
	Atypical carcinoid tumor	50 (1.09)
Tumor size	mean ± SD, mm	17.56 ± 19.69
Stage	I	1220 (57.36)
	II	504 (23.70)
	III	270 (12.69)
	IV	133 (6.25)
T stage	Tx	86 (3.86)
	Tis	7 (0.31)
	T1	1290 (57.87)
	T2	194 (8.70)
	T3	446 (20.01)
	T4	204 (9.15)
M stage	M0	2094 (94.07)
	M1	132 (5.93)
N stage	N0	2551 (81.76)
	N1	569 (18.24)
Surgery	Local resection	405 (10.34)
	Colectomy or greater	3513 (89.66)
ELNs	mean ± SD	16.54 ± 10.81
LNR	mean ± SD	0.26 ± 0.28
Survival duration	mean ± SD, mo	64.57 ± 89.96

ELNs: Examined lymph nodes; LNR: Lymph node ratio (the ratio of positive lymph nodes to the total lymph nodes examined).